Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
- Authors
- Type
- Published Article
- Journal
- Nature Communications
- Publisher
- Springer Nature
- Publication Date
- Oct 05, 2021
- Volume
- 12
- Issue
- 1
- Identifiers
- DOI: 10.1038/s41467-021-25982-w
- Source
- Springer Nature
- License
- Green
Abstract
Emerging variants of SARS-CoV-2 raise concerns about vaccine efficiency. Here, the authors present a post-hoc analysis for the ChAdOx1 nCoV-19 (AZD1222) vaccine trial in Brazil and provide efficacy against symptomatic COVID-19 caused by the Zeta (P.2) and other variants.